GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GSK GlaxoSmithKline PLC

Pre-Market Trading 11-22 09:15:43 EST

33.70

+0.35

+1.05%

盘前33.79

+0.09+0.27%

08:49 EST

High33.70	Low33.18	Vol7.03M
Open33.40	D1 Closing33.35	Amplitude1.57%
Mkt Cap68.76B	Tradable Cap67.67B	Total Shares2.04B
T/O235.37M	T/O Rate0.35%	Tradable Shares2.01B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"GlaxoSmithKline PLC","latestPrice":33.7,"timestamp":1732222800000,"preClose":33.35,"halted":0,"volume":7030641,"hourTrading":{"tag":"盘前","latestPrice":33.79,"preClose":33.7,"latestTime":"08:49 EST","volume":12873,"amount":433092.38931,"timestamp":1732283381923},"delay":0,"floatShares":2007999999,"shares":2040249850,"eps":1.629535,"marketStatus":"Pre-Market Trading","change":0.35,"latestTime":"11-22 09:15:43 EST","open":33.4,"high":33.7,"low":33.175,"amount":235374998.33965498,"amplitude":0.015742,"askPrice":33.78,"askSize":1200,"bidPrice":33.76,"bidSize":2400,"shortable":3,"etf":0,"ttmEps":1.629535,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":33.7,"dividendRate":0.045271,"preHourTrading":{"tag":"盘前","latestPrice":33.79,"preClose":33.7,"latestTime":"08:49 EST","volume":12873,"amount":433092.38931,"timestamp":1732283381923},"postHourTrading":{"tag":"盘后","latestPrice":33.72,"preClose":33.7,"latestTime":"19:10 EST","volume":108529,"amount":3657415.1968,"timestamp":1732234253746},"volumeRatio":0.762702194730415,"impliedVol":0.2442,"impliedVolPercentile":0.6414},"requestUrl":"/m/hq/s/GSK/tweets","defaultTab":"tweets","newsList":[{"id":"2485251602","title":"GSK's RSV Vaccine Approved for Japanese Patients in Their 50s","url":"https://stock-news.laohu8.com/highlight/detail?id=2485251602","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485251602?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:05","pubTimestamp":1732277125,"startTime":"0","endTime":"0","summary":"GSK  said Friday that Japan's Ministry of Health, Labour and Welfare has approved an extension of the indication of Arexvy for the prevention of respiratory syncytial virus disease to include adults aged 50 to 59 at increased risk.Since Sept. 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over.RSV is a common virus affecting the respiratory system and can, in vulnerable populations, lead to pneumonia, hospitalization, or death.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","LU1829250122.USD","GSK","BK4585","BK4007","BK4588","GSK.UK"],"gpt_icon":0},{"id":"2485628463","title":"GSK Expands RSV Vaccine Approval in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2485628463","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485628463?lang=en_us&edition=fundamental","pubTime":"2024-11-22 15:14","pubTimestamp":1732259663,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline (GB:GSK) has released an update. GlaxoSmithKline has expanded the approval of its RSV vaccine, Arexvy, in Japan to include adults a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-rsv-vaccine-approval-in-japan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-rsv-vaccine-approval-in-japan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4007","BK4532","BK4585","GSK","BK4588","LU1829250122.USD"],"gpt_icon":0},{"id":"2485401655","title":"Scott Power: Global health markets wobble as Trump picks RFK Jr for top health role","url":"https://stock-news.laohu8.com/highlight/detail?id=2485401655","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485401655?lang=en_us&edition=fundamental","pubTime":"2024-11-22 12:30","pubTimestamp":1732249833,"startTime":"0","endTime":"0","summary":"ASX health stocks fall 0.5% in past five days as RFK Jr appointed Secretary of US Department of Health and Human Services. CSL among global vaccination companies to fall following appointment of RFK Jr, a reported vaccine skeptic. Pathology and radiology giant Sonic Healthcare up after providing positive trading update at its AGM","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/11/1200-10-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/11/1200-10-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stockhead.com.au/health/scott-power-global-health-markets-wobble-as-trump-picks-rfk-jr-for-top-health-role/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["PW","SG9999015341.SGD","CDC","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU0965509101.SGD","SG9999001176.USD","SG9999014559.SGD","SG9999014567.USD","PFE","LU1941712348.USD","GSK.UK","LU0225284248.USD","LU2089984988.USD","LU0320765489.SGD","IE00B2B36J28.USD","LU1116320901.HKD","HHS","LU1037948897.HKD","MRK","LU2468319806.SGD","BK4588","IE0002141913.USD","BK4234","GSK","LU0265550359.USD","LU0211331839.USD","LU0965509283.SGD","LU0070302665.USD","SG9999002232.USD","IE00B19Z3581.USD","LU1934455277.USD","LU0265550946.USD","LU2361045086.USD","IE00BLSP4452.SGD","LU1037948541.HKD","LU1989771016.USD","LU0106261372.USD","BK4585","BK4550","LU1983299246.USD","BK4534","BK4559","LU1066051498.USD","LU2023250504.SGD","LU2106854487.HKD","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU1974910355.USD","LU0306806265.USD"],"gpt_icon":1},{"id":"2485495214","title":"Science 37 nearly doubles U.S. enrollment for GSK Phase 3 rare disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485495214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485495214?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:11","pubTimestamp":1732194667,"startTime":"0","endTime":"0","summary":"Science 37 (SNCE) was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","GSK","BK4585","BK4007","BK4121","LU1829250122.USD","SNCE","BK4532","BK4588"],"gpt_icon":0},{"id":"2485949562","title":"Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485949562","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485949562?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":"MORRISVILLE, N.C., Nov.  21, 2024  (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare diseas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985154/0/en/Science-37-Nearly-Doubles-U-S-Enrollment-for-GSK-Phase-3-Rare-Disease-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BK4532","BK4585","BK4588","GSK.UK","LU1829250122.USD","BK4007","PBC"],"gpt_icon":0},{"id":"2485777178","title":"CDC warns of an imminent spike in COVID, flu cases","url":"https://stock-news.laohu8.com/highlight/detail?id=2485777178","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485777178?lang=en_us&edition=fundamental","pubTime":"2024-11-21 04:17","pubTimestamp":1732133874,"startTime":"0","endTime":"0","summary":"angelp/iStock via Getty ImagesThe Centers for Disease Control and Prevention  on Wednesday warned Americans against an impending rise in the transmission of respiratory viruses, particularly COVID and flu, in the coming weeks as the holiday season approaches. Respiratory disease activity typically peaks in the U.S. from around December to February, with flu, COVID-19, and respiratory syncytial virus  dominating the transmissions during fall and winter. While the virus activity remains low countrywide currently, \"CDC anticipates that will change,\" the agency said, adding that the southern and eastern U.S. has already seen a rise in RSV activity, particularly among children. \"The holidays are coming, and large gatherings, travel, and more time indoors can mean more viruses spreading,\" the agency said. Noting that many Americans have yet to receive flu, COVID-19, and RSV vaccines, the CDC emphasized that \"the most important action is getting the immunizations recommended for you.\" Makers ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1447210141/image_1447210141.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1447210141/image_1447210141.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4313698-cdc-warns-against-spike-in-covid-flu-cases","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4534","BK4599","BK4550","IE00BLSP4239.USD","LU0225771236.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU0225284248.USD","BK4501","GSK.UK","IE000M9KFDE8.USD","LU1829250122.USD","LU0321505439.SGD","IE00BFXG1179.USD","BK4532","BK4551","BK4592","IE00B19Z3B42.SGD","LU1894683264.USD","LU0868494617.USD","IE00BBT3K403.USD","LU0306807586.USD","LU0306806265.USD","MRNA","SG9999002224.SGD","LU1894683348.USD","BK4139","SG9999011175.SGD","IE00B19Z3581.USD","BK4007","LU0058720904.USD","LU0985481810.HKD","LU1883839398.USD","LU0170899867.USD","LU0234572021.USD","BK4548","BK4533","IE00BLSP4452.SGD","LU0456855351.SGD","LU1057294990.SGD","PFE","SG9999002232.USD","BK4588","SNY","SG9999001176.USD","BK4581","GSK"],"gpt_icon":1},{"id":"2484903667","title":"Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903667","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903667?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:54","pubTimestamp":1732042440,"startTime":"0","endTime":"0","summary":"Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2  in chronic spontaneous urticaria .Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading.Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline.Incyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings.The data was also shared with the FDA. The company is now working closely with the FDA to determine the next steps.Additionally, data from the phase II study evaluating MRGPRX4 in cholestatic pruritus does not support further development.IMCR’s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-pauses-enrollment-chronic-spontaneous-185400622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","GSK","BK4539","BK4563","IMCR","BK4196","CSTL","BK4007","BK4588","LU1829250122.USD","INCY","BK4550","GSK.UK","MF","BK4113","BK4532","BK4526","BK4505"],"gpt_icon":0},{"id":"2484971418","title":"GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2484971418","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484971418?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:24","pubTimestamp":1732040656,"startTime":"0","endTime":"0","summary":"On Tuesday, GSK plc  released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus  associated with primary biliary cholangitis , a rare autoimmune liver disease.GLISTEN met its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo.Also Read: GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market – Here’s Why. The trial recruited PBC patients with moderate to severe itch who were receiving stable doses of guideline-suggested therapies for pruritus, were treatment nave, or had been previously treated.The preliminary safety results are generally consistent with those seen in prior studies of linerixibat. Further analysis of these data is ongoing.People who have been diagnosed with PBC will reach 510,000 globally by 2030, and more than 240,000 people will experience relentless itch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pG_Y.M3QkKyixiGDmtURDA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d0ed0f9470b88069294682599fa24b60","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pG_Y.M3QkKyixiGDmtURDA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d0ed0f9470b88069294682599fa24b60"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsks-investigational-liver-disease-candidate-182416125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4007","BK4585","IE00BFMHRM44.USD","BK4023","PBC","SSI","GSK.UK","BK4566","NICE","BK4532","LU1829250122.USD","GSK"],"gpt_icon":0},{"id":"2484205429","title":"GSK reports positive Phase 3 results for linerixibat in PBC itching","url":"https://stock-news.laohu8.com/highlight/detail?id=2484205429","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484205429?lang=en_us&edition=fundamental","pubTime":"2024-11-20 00:01","pubTimestamp":1732032117,"startTime":"0","endTime":"0","summary":"Wirestock/iStock Editorial via Getty Images GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary biliary cholangitis, or PBC, met its primary endpoint. The U.K. drugmaker said data showed a significant reduction in baseline in","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442119524/image_1442119524.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4307531-gsk-reports-positive-phase-3-results-for-linerixibat-in-pbc-itching","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4532","BK4585","GSK.UK","BK4588","GSK","BK4007","LU1829250122.USD"],"gpt_icon":0},{"id":"2484774929","title":"GSK Executives Acquire ADSs, Aligning Interests with Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2484774929","media":"TIPRANKS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484774929?lang=en_us&edition=fundamental","pubTime":"2024-11-19 23:32","pubTimestamp":1732030338,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline (GB:GSK) has released an update. GSK plc has announced the acquisition of American Depositary Shares (ADSs) by Dr Hal Barron, a Non...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-adss-aligning-interests-with-shareholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-executives-acquire-adss-aligning-interests-with-shareholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GSK.UK","BK4588","GSK","BK4007","BK4532","LU1829250122.USD"],"gpt_icon":0},{"id":"2484594878","title":"GSK Says Trial of Itch Treatment Linerixibat Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2484594878","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484594878?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:16","pubTimestamp":1732018606,"startTime":"0","endTime":"0","summary":"GSK  said Tuesday that an ongoing phase 3 trial evaluating linerixibat in adults with cholestatic pruritus, or relentless itching, associated with primary biliary cholangitis met its primary endpoint of significantly improving itch over 24 weeks compared with placebo.The company said the improvement was demonstrated by a \"statistically significant\" reduction from baseline in monthly itch score. GSK said preliminary safety results are \"generally consistent\" with prior studies, but further data analysis continues.Full results of the trial will be presented at a future scientific congress, GSK said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","GSK","GSK.UK","BK4585","LU1829250122.USD","BK4007","BK4532"],"gpt_icon":0},{"id":"2484912699","title":"GSK announces phase III trial of linerixibat met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2484912699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484912699?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:25","pubTimestamp":1732015556,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-phase-iii-trial-of-linerixibat-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-phase-iii-trial-of-linerixibat-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4588","BK4532","BK4585","III","LU1829250122.USD","BK4007","BK4134","GSK"],"gpt_icon":0},{"id":"2484960478","title":"BRIEF-GSK Meets Primary Endpoint in Late-Stage Trial To Treat Relentless Itch","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960478","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484960478?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:15","pubTimestamp":1732000524,"startTime":"0","endTime":"0","summary":"Nov 19  - GSK plc   :   * GSK PLC  - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT   * GSK PLC  - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT   * GSK PLC - LINERIXIBAT SHOWS POSITIVE PHASE III RESULTS IN PBC ITCH   * GSK PLC - PRIMARY ENDPOINT MET WITH SIGNIFICANT IMPROVEMENT IN ITCH   * GSK - PRIMARY ENDPOINT MET WITH A STATISTICALLY SIGNIFICANT IMPROVEMENT IN ITCH OVER 24 WEEKS COMPARED WITH PLACEBO   * GSK - LINERIXIBAT HAS POTENTIAL TO BE FIRST GLOBAL THERAPY INDICATED TO TREAT ITCH IN PBCSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","SSI","GSK.UK","BK4007","LU1829250122.USD","GSK","BK4588","BK4585"],"gpt_icon":0},{"id":"2484960392","title":"GSK’s Linerixibat Shows Promise for PBC Itch Relief","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484960392?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:10","pubTimestamp":1732000259,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline (GB:GSK) has released an update. GlaxoSmithKline (GSK) has announced promising Phase III trial results for linerixibat, a potential...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-linerixibat-shows-promise-for-pbc-itch-relief?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-linerixibat-shows-promise-for-pbc-itch-relief?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","BK4588","BK4585","BK4007","GSK.UK","PBC","LU1829250122.USD","BK4532"],"gpt_icon":0},{"id":"2484629090","title":"Press Release: Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484629090","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484629090?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:30","pubTimestamp":1731933000,"startTime":"0","endTime":"0","summary":"Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program. TORONTO and PHILADELPHIA, Nov. 18, 2024  -- Medicus Pharma Ltd   is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer.Most recently, Dr. Mehmud was the Senior Vice President, Data Generation and Scientific Communications in Worldwide Global Medical Affairs at GlaxoSmithKline , which included leadership of medical affairs sponsored and supported, interventional and non-interventional clinical trials. Before GSK, Dr. Mehmud was with Pfizer Inc., where he served in various roles including as Vice President and Worldwide Medical Franchise Head for Precision Medicine and Early Oncology Development, advancing the precision medicine oncology portfolio in a variety of tumor types, and supporting early-stage oncology projects moving from early clinical development to full development and market readiness, effectively bridging scientific innovation with commercial strategy.Dr. Meh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1883839398.USD","LU1894683264.USD","IE00BBT3K403.USD","BK4196","BK4585","SGXZ57979304.SGD","SG9999013999.USD","LU0306807586.USD","LU0122379950.USD","LU0289739699.SGD","LU0321505439.SGD","IE00B19Z3581.USD","LU1057294990.SGD","LU0058720904.USD","IE0002270589.USD","LU1894683348.USD","LU1066053197.SGD","BK4533","BMS","LU1023059063.AUD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU0225284248.USD","LU1829250122.USD","LU0868494617.USD","LU0985481810.HKD","GSK","IE00BLSP4239.USD","BK4532","MDCX","LU0306806265.USD","SG9999003800.SGD","LU0321505868.SGD","SG9999002232.USD","MD","LU1066051498.USD","BK4568","SG9999001176.SGD","BK4534","LU0170899867.USD","BK4581","MRCP","BK4588","BK4592","BK4007","IE00B19Z3B42.SGD","PFE","GSK.UK","LU0225771236.USD"],"gpt_icon":1},{"id":"2483581328","title":"Vaccine stocks drop on concerns about RFK Jr. heading HHS (update)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483581328","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483581328?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:08","pubTimestamp":1731690507,"startTime":"0","endTime":"0","summary":"Morsa Images Shares of several of the world’s largest vaccine makers fell significantly Friday, the day after President-elect Donald Trump announced he had selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services, which oversees vaccine authorizations for the U.S. market.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4295685-vaccine-stocks-drop-on-concerns-about-rfk-jr-heading-hhs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["MRK","LU0225284248.USD","SG9999001440.SGD","SG9999001176.SGD","LU0320765489.SGD","IE0002141913.USD","GSK","LU1093756168.USD","LU2112291526.USD","LU0238689110.USD","GSK.UK","LU2461242641.AUD","LU0965509283.SGD","BVNRY","LU0122379950.USD","LU1057294990.SGD","LU2361044865.SGD","LU1066053197.SGD","LU1941712348.USD","BK4532","LU0203347892.USD","AZN","LU0985481810.HKD","LU1037948897.HKD","LU1894683348.USD","BNTX","BVNKF","BK4548","IE00BLSP4239.USD","PFE","LU0965509010.AUD","LU0320765992.SGD","NVAX","EBS","SG9999002232.USD","LU1116320901.HKD","MRNA","SGXZ57979304.SGD","IE00B2B36J28.USD","LU1291159041.SGD","SG9999015341.SGD","LU0006306889.USD","LU0266013472.USD","HHS","LU1585245621.USD","LU1934455194.USD","LU1989771016.USD","LU0170899867.USD","LU0456855351.SGD","IE0009355771.USD"],"gpt_icon":0},{"id":"2483930329","title":"Stock Market Today: Dow Jones Slumps 250 Points As Yields Spike; Warren Buffett Targets Pizza, Pools With New Buys (Live Coverage)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483930329","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483930329?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:22","pubTimestamp":1731684130,"startTime":"0","endTime":"0","summary":"Sellers hit tech stocks in stock market today as bond yields spiked, but selling was muted in the Russell 2000 small-cap index.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/stock-bull-bear-figurines-close-1-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/stock-bull-bear-figurines-close-1-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-retail-sales-warren-buffett-new-buys/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0128525689.USD","AMAT","GSK.UK","TSLA","LU1152091754.HKD","CHTR","LRCX","POOL","DPZ","ULTA","AZN","BRK.B","LU1674673428.USD","IE00B775SV38.USD","BK4548","IE00BFSS7M15.SGD","LU0234572021.USD","LU0823411888.USD","PFE.AU","LU0821914370.USD","LU1051768304.USD","BK4533","09988","LU0208291251.USD","LU0477156953.USD","LU2023250504.SGD","SMH","BK4518","BK4141","PCOM","BK4503","IE00BQXX3C00.GBP","IE00BKDWB100.SGD","GSK","SG9999013999.USD","LU0306807586.USD","NVAX","COF","ARM.AU","NQmain","LU1548497426.USD","LU1670627923.USD","LU0797268264.HKD","LU0820561909.HKD","PLTR","COF.AU","BABA"],"gpt_icon":1},{"id":"1167978426","title":"Vaccine Maker Stocks Fall as Trump Chooses RFK Jr. to Lead HHS","url":"https://stock-news.laohu8.com/highlight/detail?id=1167978426","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167978426?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:21","pubTimestamp":1731684110,"startTime":"0","endTime":"0","summary":"Shares of vaccine makers fell Friday as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services.Moderna fell 6.2%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BNTX","MRNA","NVAX","PFE"],"gpt_icon":1},{"id":"2483937718","title":"Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483937718","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483937718?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:43","pubTimestamp":1731681831,"startTime":"0","endTime":"0","summary":"Vaccine and other healthcare stocks fell Friday after President-elect Donald Trump said Robert F. Kennedy Jr. is his pick to lead the U.S. Health and Human Services Department . But some analysts think the reaction may overstate the changes RFK might bring to the agency.\"Admittedly, it is difficult to evaluate the exact impact this appointment could have on the industry until we have more information on specific policy proposals and priorities of the incoming administration on healthcare and the drug industry,\" wrote J.P. Morgan analyst Chris Schott in a note to clients Friday.Here's why there's concern: RFK Jr., a vocal skeptic of the drug approval process, will be able to select leaders of all the health departments under HHS, including the U.S. Food and Drug Administration , and Centers for Disease Control and Prevention , as well as the head of the Centers for Medicare and Medicaid Services .\"We are not surprised the sector has been under pressure on the potential for RFK Jr. havin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/emHdgB9da71X.ovzf_goGQ--~B/aD0zMTkxO3c9NDc4NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2024-11/d78a1dd0-a357-11ef-bfd7-7379c5ff40c5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/emHdgB9da71X.ovzf_goGQ--~B/aD0zMTkxO3c9NDc4NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2024-11/d78a1dd0-a357-11ef-bfd7-7379c5ff40c5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-think-wall-streets-reaction-to-the-rfk-jr-news-is-overdone-sort-of-144351507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","LU0109394709.USD","CDC","LU2361044865.SGD","LU0965509101.SGD","MRNA","SG9999001176.USD","SNY","PFE","IE00BN8TJ469.HKD","GSK.UK","IE00B1BXHZ80.USD","LU0225284248.USD","BK4568","LU0320765489.SGD","LU0985320562.USD","LU1023059063.AUD","CMS","HHS","LU1894683348.USD","MRK","LU0225771236.USD","LU1093756325.SGD","BK4139","LU1057294990.SGD","SG9999015358.SGD","AZN","GSK","SG9999001176.SGD","BK4208","LU0211331839.USD","LU0070302665.USD","SG9999002232.USD","LU1116320737.USD","IE00B19Z3581.USD","BK4533","LU0265550946.USD","LU1934455277.USD","SG9999013999.USD","LU2456880835.USD","LU2462157665.USD","LU1037948541.HKD","LU0203347892.USD","BK4585","BK4532","LU2023250504.SGD","BK4581","SG9999014542.SGD","IE00B4R5TH58.HKD","LU2361044949.HKD"],"gpt_icon":1},{"id":"2483373932","title":"Trump's RFK Pick Weighs on Vaccine Makers -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2483373932","media":"Dow Jones","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483373932?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:08","pubTimestamp":1731676080,"startTime":"0","endTime":"0","summary":"By Liz Essley Whyte, Andrew Restuccia and Vivian Salama. WASHINGTON -- President-elect Donald Trump's nomination of environmental lawyer and vaccine skeptic  Robert F. Kennedy Jr.as health and human services secretary continued to reverberate through the pharmaceutical industry Friday.Kennedy has promised sweeping changes to food-and-drug regulation and government-funded scientific research, in recent days saying the Food and Drug Administration's nutrition department needed to be eliminated and warning the agency's employees to \"pack your bags.\". Kennedy, 70 years old, abandoned his independent presidential bid in August and endorsed Trump, promising that he and the Republican would work to \"make America healthy again.\". Billionaire Elon Musk and one of the president-elect's sons, Donald Trump Jr., both advocated behind the scenes for Trump to pick Kennedy, according to people familiar with the discussions. Trump transition team co-chair Howard Lutnick previously had said that Kennedy","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4592","BK4551","LU0109394709.USD","LU0985481810.HKD","IE000M9KFDE8.USD","MRNA","LU0234572021.USD","SNY","LU0170899867.USD","PFE","GSK.UK","IE00BFXG1179.USD","LU1023059063.AUD","BK4568","LU0320765992.SGD","BK4501","SG9999011175.SGD","LU0321505439.SGD","LU1894683264.USD","BK4139","LU0456855351.SGD","AZN","GSK","SG9999001176.SGD","SG9999002224.SGD","IE00BBT3K403.USD","LU0058720904.USD","BK4548","SG9999002232.USD","IE00B19Z3581.USD","BK4533","SG9999013999.USD","LU2456880835.USD","IE00BLSP4452.SGD","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","SG9999003800.SGD","LU1066053197.SGD","LU0306807586.USD","BK4550","BK4585","BK4534","LU2417539215.USD","BK4532","LU0306806265.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.0201},{"period":"1month","weight":-0.1132},{"period":"3month","weight":-0.2095},{"period":"6month","weight":-0.2531},{"period":"1year","weight":-0.0426},{"period":"ytd","weight":-0.0907}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.568182,"avgChangeRate":0.012276},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.003512},{"month":3,"riseRate":0.613636,"avgChangeRate":0.0208},{"month":4,"riseRate":0.666667,"avgChangeRate":0.032721},{"month":5,"riseRate":0.4,"avgChangeRate":-0.008934},{"month":6,"riseRate":0.6,"avgChangeRate":0.011286},{"month":7,"riseRate":0.555556,"avgChangeRate":0.004756},{"month":8,"riseRate":0.577778,"avgChangeRate":0.004428},{"month":9,"riseRate":0.511111,"avgChangeRate":0.004151},{"month":10,"riseRate":0.511111,"avgChangeRate":0.011448},{"month":11,"riseRate":0.466667,"avgChangeRate":0.009403},{"month":12,"riseRate":0.613636,"avgChangeRate":0.014479}],"exchange":"NYSE","name":"GlaxoSmithKline PLC","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GlaxoSmithKline PLC,GSK,GlaxoSmithKline PLC股票,GlaxoSmithKline PLC股票老虎,GlaxoSmithKline PLC股票老虎国际,GlaxoSmithKline PLC行情,GlaxoSmithKline PLC股票行情,GlaxoSmithKline PLC股价,GlaxoSmithKline PLC股市,GlaxoSmithKline PLC股票价格,GlaxoSmithKline PLC股票交易,GlaxoSmithKline PLC股票购买,GlaxoSmithKline PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction